Briefcases -- Drugs -- ACTEMRA (tocilizumab) by Genentech USA, Inc. (Roche Group)

ACTEMRA (tocilizumab) by Genentech USA, Inc. (Roche Group)

Case Files
News
Committees
Request a Document
Request
Search Within Briefcase

Categories

  1. Single Event Case Filings
  2. Media References
  3. FDA Regulatory Materials

Documents

Sort by:
  1. ACTEMRA (tocilizumab) STAT Report (March 28, 2013)
  2. ACTEMRA (tocilizumab) FDA Meeting Summary (June 26, 2008)
  3. ACTEMRA (tocilizumab) FDA Label (March 2017)
  4. ACTERMA (tocilizumab) Australian TAG Public Assessment Report (January 2015)
  5. ACTEMRA (tocilizumab) Letter to Healthcare Providers (October 2013)
  6. ACTEMRA (tocilizumab) FDA Clinical Pharmacology Reviews (January 29, 2013)
  7. ACTERMA (tocilizumab) Article "Treatment options in patients with rheumatoid arthritis failing" (published April 6, 2009)
  8. ACTEMRA (tocilizumab) FDA Label (May 2017)
  9. ACTEMRA (tocilizumab) Fordham IP Institute "Current Developments in U.S. Patent Law" by Dimitrios T. Drivas (April 24, 2014)
  10. ACTEMRA (tocilizumab) FDA Microbiology / Virology Review(s) (October 11, 2013)
  11. ACTEMRA (tocilizumab) FDA Other Review(s) (February 4, 2013)
  12. ACTEMRA (tocilizumab) FDA Environmental Assessment (January 24, 2013)
  13. ACTERMA (tocilizumab) FDA Label (October 2012)
  14. ACTERMA (tocilizumab) Rheumatology News_"Tocilizumab raises cholesterol, but not cardiovascular events" (published December 7, 2016)
  15. Tocilizumab raises cholesterol, but not cardiovascular events _ Rheumatology News.pdf
  16. RoACTEMRA (tocilizumab) EMA Summary of Opinion (July 20, 2017)
  17. ACTEMRA (tocilizumab) BLA Supplement Approval (May 22, 2017)
  18. ACTEMRA (tocilizumab) Australian Rheumatology Association Patient Information (February 2017)
  19. ACTERMA (tocilizumab) FDA Label (September 2016)
  20. ACTEMRA (tocilizumab) Australian TAG Public Assessment Report Attachment 1 (January 21, 2016)
  21. ACTERMA (tocilizumab) FDA Supplement Approval_REMS Modification (August 18, 2015)
  22. ACTERMA (tocilizumab) IRF Pilot Trial Summary_University Hospital of Parma, Italy (June 19, 2015)
  23. ACTEMRA (tocilizumab) Rheumatology News "Tocilizumab and tofacitinib increase lipids in RA patients" (October 17, 2014)
  24. ACTEMRA (tocilizumab) Scottish Medicines Consortium Product Use Advisory (August 11, 2014)
  25. ACTEMRA (tocilizumab) Elsevier Seminars "Tocilizumab in rheumatoid arthritis: A case study of safety evaluations . . ." (2014)
  26. ACTEMRA (tocilizumab) FDA Label Approval Letter (October 21, 2013)
  27. ACTEMRA (tocilizumab) FDA Summary Review (October 21, 2013)
  28. ACTEMRA (tocilizumab) FDA Risk Assessment and Risk Mitigation Review(s) (October 16, 2013)
  29. ACTEMRA (tocilizumab) FDA Other Review(s) (October 2013)
  30. ACTERMA (tocilizumab) FDA Injection Label (October 2013)
  31. ACTEMRA (tocilizumab) FDA Label (October 2013)
  32. ACTEMRA (tocilizumab) FDA Proprietary Name Review(s) (August 9, 2013)
  33. ACTEMRA (tocilizumab) FDA Label (April 2013)
  34. ACTEMRA (tocilizumab) FDA Statistical Review(s) (January 31, 2013)
  35. ACTEMRA (tocilizumab) Pharmacology Review(s) (January 23, 2013)
  36. ACTEMRA (tocilizumab) FDA Chemistry Reviews (2013)
  37. ACTEMRA (tocilizumab) FDA Label (August 2012)
  38. ACTERMA (tocilizumab) NHS UK Drug Evaluation "The role of tocilizumab monotherapy in the management of rheumatoid arthritis . . ." (2012)
  39. ACTEMRA (tocilizumab) FDA Label (April 2011)
  40. ACTEMRA (tocilizumab) FDA Label (January 2011)
  41. ACTERMA (tocilizumab) Health Canada Recall Letter (September 17, 2010)
  42. ACTERMA (tocilizumab) BC Cancer Agency Cancer Drug Manual (June 16, 2010)
  43. ACTERMA (tocilizumab) FDA BLA Approval (January 8, 2010)
  44. ACTEMRA (tocilizumab) FDA Label (January 2010)
View All